Gregg D Smith

发表

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

A. Roberts, M. Wadleigh, A. Tefferi, 2011 .

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

S. Verstovsek, R. Mesa, F. Passamonti, 2020 .

PI 3-kinase p110beta: a new target for antithrombotic therapy.

A. Robertson, P. Shepherd, P. Thompson, 2005, Nature medicine.

Pharmacokinetics and brain uptake of AM‐36, a novel neuroprotective agent, following intravenous administration to rats

S. Charman, J. Nicolazzo, J. Callaway, 2008, The Journal of pharmacy and pharmacology.

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.

M. Warr, K. Wagner, C. Burns, 2017, Blood.

PI 3-kinase p110β: a new target for antithrombotic therapy

A. Robertson, P. Shepherd, P. Thompson, 2005, Nature Medicine.

The Microtubule Depolymerizing Agent CYT997 Causes Extensive Ablation of Tumor Vasculature In Vivo

P. Cooper, A. Wilks, E. Fantino, 2011, Journal of Pharmacology and Experimental Therapeutics.

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

P. Vasey, A. Wilks, M. burge, 2012, Investigational New Drugs.

CYT997 Causes apoptosis in human multiple myeloma

K. Monaghan, A. Spencer, T. Khong, 2011, Investigational New Drugs.

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

A. Coulthard, M. Griffin, P. Vasey, 2010, British Journal of Cancer.

A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms

A. Tefferi, C. Burns, T. Lasho, 2010 .